AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.89+1.96 (+1.80%) ▲|ACN187.69-0.40 (-0.21%) ▼|ADBE280.82-5.27 (-1.84%) ▼|AMAT438.52-3.33 (-0.75%) ▼|AMD456.62-2.99 (-0.65%) ▼|AMGN441.36+3.24 (+0.74%) ▲|AMT172.50-3.53 (-2.00%) ▼|AMZN255.12+0.20 (+0.08%) ▲|AVGO368.94-0.75 (-0.20%) ▼|AXP329.70+5.51 (+1.70%) ▲|BA208.84+3.18 (+1.55%) ▲|BAC62.64+0.65 (+1.05%) ▲|BKNG199.42+3.73 (+1.91%) ▲|BLK1,111.54-16.56 (-1.47%) ▼|BMY67.71+0.79 (+1.18%) ▲|BNY162.20+1.69 (+1.05%) ▲|BRK-B505.20+2.87 (+0.57%) ▲|C134.30+1.76 (+1.33%) ▲|CAT790.36+11.20 (+1.44%) ▲|CL90.23+0.60 (+0.67%) ▲|CMCSA26.88+0.58 (+2.19%) ▲|COF216.92+5.58 (+2.64%) ▲|COP137.24+1.05 (+0.77%) ▲|COST921.73-18.23 (-1.94%) ▼|CRM258.33+0.22 (+0.09%) ▲|CSCO109.47-0.27 (-0.25%) ▼|CVS97.19-0.41 (-0.42%) ▼|CVX212.49+1.44 (+0.68%) ▲|DE691.98+15.90 (+2.35%) ▲|DHR209.65+2.72 (+1.31%) ▲|DIS108.46+2.24 (+2.11%) ▲|DUK120.57+0.18 (+0.15%) ▲|EMR149.10+1.47 (+1.00%) ▲|FDX317.89-6.99 (-2.15%) ▼|GD365.98-3.43 (-0.93%) ▼|GE330.31-0.78 (-0.24%) ▼|GEV921.89+23.36 (+2.60%) ▲|GILD149.58-0.35 (-0.23%) ▼|GM84.80-0.84 (-0.98%) ▼|GOOG334.31+2.28 (+0.69%) ▲|GOOGL337.76+2.74 (+0.82%) ▲|GS1,005.10+2.54 (+0.25%) ▲|HD317.95-1.82 (-0.57%) ▼|HON205.35-4.63 (-2.21%) ▼|IBM231.78+0.38 (+0.16%) ▲|INTC89.77+0.80 (+0.90%) ▲|INTU343.00-1.94 (-0.56%) ▼|ISRG370.69+1.44 (+0.39%) ▲|JNJ275.44+4.25 (+1.57%) ▲|JPM355.86+0.91 (+0.26%) ▲|KO88.57+0.57 (+0.64%) ▲|LIN488.47+1.71 (+0.35%) ▲|LLY1,164.70+4.70 (+0.41%) ▲|LMT533.83-10.68 (-1.96%) ▼|LOW199.95-0.10 (-0.05%) ▼|LRCX287.31-2.90 (-1.00%) ▼|MA588.70+7.60 (+1.31%) ▲|MCD260.27-0.85 (-0.32%) ▼|MDLZ62.53+0.92 (+1.49%) ▲|MDT92.84+0.80 (+0.87%) ▲|META595.21+16.67 (+2.88%) ▲|MMM168.31-1.93 (-1.13%) ▼|MO69.67+0.10 (+0.14%) ▲|MRK151.69+1.83 (+1.22%) ▲|MS212.29+1.25 (+0.59%) ▲|MSFT496.75-4.27 (-0.85%) ▼|MU952.16+18.72 (+2.00%) ▲|NEE82.93-0.01 (-0.01%) ▼|NFLX82.39+1.58 (+1.95%) ▲|NKE38.25+0.13 (+0.33%) ▲|NOW137.17-5.73 (-4.01%) ▼|NVDA224.69+7.25 (+3.33%) ▲|ORCL146.16+4.84 (+3.42%) ▲|PEP140.42+0.63 (+0.45%) ▲|PFE29.04+0.49 (+1.72%) ▲|PG147.61+1.40 (+0.96%) ▲|PLTR169.24-10.68 (-5.94%) ▼|PM187.20+0.05 (+0.02%) ▲|QCOM169.75+3.14 (+1.88%) ▲|RTX201.54-3.63 (-1.77%) ▼|SBUX107.13+0.98 (+0.92%) ▲|SCHW109.00+0.72 (+0.66%) ▲|SO88.25+0.16 (+0.18%) ▲|SPG209.49-2.38 (-1.12%) ▼|T26.04+0.04 (+0.14%) ▲|TMO608.84+8.34 (+1.39%) ▲|TMUS186.77+4.61 (+2.53%) ▲|TSLA352.94-3.15 (-0.88%) ▼|TXN254.76+1.42 (+0.56%) ▲|UBER76.64+1.40 (+1.86%) ▲|UNH399.82+3.52 (+0.89%) ▲|UNP290.59-0.03 (-0.01%) ▼|UPS103.15+0.49 (+0.48%) ▲|USB62.83+1.62 (+2.65%) ▲|V379.85+7.18 (+1.93%) ▲|VZ50.35+0.05 (+0.11%) ▲|WFC89.66+2.62 (+3.01%) ▲|WMT105.92-0.01 (0.00%) ▼|XOM164.92+0.37 (+0.22%) ▲|AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.89+1.96 (+1.80%) ▲|ACN187.69-0.40 (-0.21%) ▼|ADBE280.82-5.27 (-1.84%) ▼|AMAT438.52-3.33 (-0.75%) ▼|AMD456.62-2.99 (-0.65%) ▼|AMGN441.36+3.24 (+0.74%) ▲|AMT172.50-3.53 (-2.00%) ▼|AMZN255.12+0.20 (+0.08%) ▲|AVGO368.94-0.75 (-0.20%) ▼|AXP329.70+5.51 (+1.70%) ▲|BA208.84+3.18 (+1.55%) ▲|BAC62.64+0.65 (+1.05%) ▲|BKNG199.42+3.73 (+1.91%) ▲|BLK1,111.54-16.56 (-1.47%) ▼|BMY67.71+0.79 (+1.18%) ▲|BNY162.20+1.69 (+1.05%) ▲|BRK-B505.20+2.87 (+0.57%) ▲|C134.30+1.76 (+1.33%) ▲|CAT790.36+11.20 (+1.44%) ▲|CL90.23+0.60 (+0.67%) ▲|CMCSA26.88+0.58 (+2.19%) ▲|COF216.92+5.58 (+2.64%) ▲|COP137.24+1.05 (+0.77%) ▲|COST921.73-18.23 (-1.94%) ▼|CRM258.33+0.22 (+0.09%) ▲|CSCO109.47-0.27 (-0.25%) ▼|CVS97.19-0.41 (-0.42%) ▼|CVX212.49+1.44 (+0.68%) ▲|DE691.98+15.90 (+2.35%) ▲|DHR209.65+2.72 (+1.31%) ▲|DIS108.46+2.24 (+2.11%) ▲|DUK120.57+0.18 (+0.15%) ▲|EMR149.10+1.47 (+1.00%) ▲|FDX317.89-6.99 (-2.15%) ▼|GD365.98-3.43 (-0.93%) ▼|GE330.31-0.78 (-0.24%) ▼|GEV921.89+23.36 (+2.60%) ▲|GILD149.58-0.35 (-0.23%) ▼|GM84.80-0.84 (-0.98%) ▼|GOOG334.31+2.28 (+0.69%) ▲|GOOGL337.76+2.74 (+0.82%) ▲|GS1,005.10+2.54 (+0.25%) ▲|HD317.95-1.82 (-0.57%) ▼|HON205.35-4.63 (-2.21%) ▼|IBM231.78+0.38 (+0.16%) ▲|INTC89.77+0.80 (+0.90%) ▲|INTU343.00-1.94 (-0.56%) ▼|ISRG370.69+1.44 (+0.39%) ▲|JNJ275.44+4.25 (+1.57%) ▲|JPM355.86+0.91 (+0.26%) ▲|KO88.57+0.57 (+0.64%) ▲|LIN488.47+1.71 (+0.35%) ▲|LLY1,164.70+4.70 (+0.41%) ▲|LMT533.83-10.68 (-1.96%) ▼|LOW199.95-0.10 (-0.05%) ▼|LRCX287.31-2.90 (-1.00%) ▼|MA588.70+7.60 (+1.31%) ▲|MCD260.27-0.85 (-0.32%) ▼|MDLZ62.53+0.92 (+1.49%) ▲|MDT92.84+0.80 (+0.87%) ▲|META595.21+16.67 (+2.88%) ▲|MMM168.31-1.93 (-1.13%) ▼|MO69.67+0.10 (+0.14%) ▲|MRK151.69+1.83 (+1.22%) ▲|MS212.29+1.25 (+0.59%) ▲|MSFT496.75-4.27 (-0.85%) ▼|MU952.16+18.72 (+2.00%) ▲|NEE82.93-0.01 (-0.01%) ▼|NFLX82.39+1.58 (+1.95%) ▲|NKE38.25+0.13 (+0.33%) ▲|NOW137.17-5.73 (-4.01%) ▼|NVDA224.69+7.25 (+3.33%) ▲|ORCL146.16+4.84 (+3.42%) ▲|PEP140.42+0.63 (+0.45%) ▲|PFE29.04+0.49 (+1.72%) ▲|PG147.61+1.40 (+0.96%) ▲|PLTR169.24-10.68 (-5.94%) ▼|PM187.20+0.05 (+0.02%) ▲|QCOM169.75+3.14 (+1.88%) ▲|RTX201.54-3.63 (-1.77%) ▼|SBUX107.13+0.98 (+0.92%) ▲|SCHW109.00+0.72 (+0.66%) ▲|SO88.25+0.16 (+0.18%) ▲|SPG209.49-2.38 (-1.12%) ▼|T26.04+0.04 (+0.14%) ▲|TMO608.84+8.34 (+1.39%) ▲|TMUS186.77+4.61 (+2.53%) ▲|TSLA352.94-3.15 (-0.88%) ▼|TXN254.76+1.42 (+0.56%) ▲|UBER76.64+1.40 (+1.86%) ▲|UNH399.82+3.52 (+0.89%) ▲|UNP290.59-0.03 (-0.01%) ▼|UPS103.15+0.49 (+0.48%) ▲|USB62.83+1.62 (+2.65%) ▲|V379.85+7.18 (+1.93%) ▲|VZ50.35+0.05 (+0.11%) ▲|WFC89.66+2.62 (+3.01%) ▲|WMT105.92-0.01 (0.00%) ▼|XOM164.92+0.37 (+0.22%) ▲|

22.6 C

New York

Wednesday, September 2, 2026

Fitness Ventures, Largest Crunch Fitness Franchisee, brings 106 Crunch Fitness Locations and 100+ Fire Departments Together for Nationwide 9/11 Remembrance Stair Climb Challenge

Corgi Insurance Launches ‘Corgi Re’ to Modernize Reinsurance With Technology-Driven Underwriting

TPx Secures Court Approval of Plan of Reorganization, Positioning Company for Long-Term Success

Tag: lead

Orbis International’s Flying Eye Hospital Arrives in Peru to Expand Access to Essential Eye Care

With support from Alcon, FedEx, and OMEGA, the Orbis Flying Eye Hospital returns to Peru to carry out a training project in the city of Arequipa.AREQUIPA,...

SAMARITAN’S PURSE EBOLA TREATMENT CENTERS OPEN IN THE EPICENTER OF THE DEADLY OUTBREAK

BOONE, N.C., June 14, 2026 /PRNewswire/ -- Samaritan's Purse has established two Ebola Treatment Centers in Bunia and Nyankunde, Democratic Republic of Congo (DRC), to...

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Via Transportation, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VIA

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Via Transportation, Inc. (NYSE: VIA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Via's initial public offering (the "IPO" or “Offering”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026.

SES AI DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important...

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SES AI Corporation (NYSE: SES) between January 29, 2025 and March 4, 2026, both dates inclusive (the “Class Period”), of the important June 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...